Act Two Investors LLC Buys Shares of 11,790 Johnson & Johnson (NYSE:JNJ)

Act Two Investors LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,790 shares of the company’s stock, valued at approximately $1,848,000. Johnson & Johnson makes up about 0.4% of Act Two Investors LLC’s portfolio, making the stock its 28th largest holding.

Other institutional investors also recently bought and sold shares of the company. American Institute for Advanced Investment Management LLP lifted its stake in shares of Johnson & Johnson by 4.4% during the third quarter. American Institute for Advanced Investment Management LLP now owns 7,280 shares of the company’s stock worth $1,134,000 after buying an additional 305 shares during the period. Triumph Capital Management lifted its stake in shares of Johnson & Johnson by 141.5% during the third quarter. Triumph Capital Management now owns 5,701 shares of the company’s stock worth $888,000 after buying an additional 3,340 shares during the period. Manhattan West Asset Management LLC lifted its stake in shares of Johnson & Johnson by 8.0% during the third quarter. Manhattan West Asset Management LLC now owns 1,900 shares of the company’s stock worth $288,000 after buying an additional 141 shares during the period. Tower View Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the period. Finally, Tilson Financial Group Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth $227,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Wednesday. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Price Performance

Shares of JNJ traded down $2.73 during mid-day trading on Friday, hitting $146.97. 9,520,576 shares of the company were exchanged, compared to its average volume of 7,234,254. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a 50 day moving average of $151.31 and a 200-day moving average of $155.07. The stock has a market cap of $353.71 billion, a price-to-earnings ratio of 9.16, a price-to-earnings-growth ratio of 2.44 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the firm earned $2.68 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.